Neuronetics Inc
$ 2.38
5.78%
07 Aug - close price
- Market Cap 165,619,000 USD
- Current Price $ 2.38
- High / Low $ 2.42 / 2.26
- Stock P/E N/A
- Book Value 0.19
- EPS -0.57
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -1.32 %
- 52 Week High 4.29
- 52 Week Low 0.80
About
Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company is headquartered in Malvern, Pennsylvania.
Analyst Target Price
$4.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-03-17 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-03-04 | 2024-11-12 | 2024-08-12 | 2024-05-07 | 2024-03-05 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -0.15 | -0.1 | -0.13 | -0.15 | -0.21 | -0.33 | -0.44 | -0.33 | -0.27 | -0.19 | -0.33 | -0.17 |
| Estimated EPS | -0.17 | -0.11 | -0.12 | -0.08 | -0.12 | -0.24 | -0.23 | -0.27 | -0.31 | -0.26 | -0.28 | -0.35 |
| Surprise | 0.02 | 0.01 | -0.01 | -0.07 | -0.09 | -0.09 | -0.21 | -0.06 | 0.04 | 0.07 | -0.05 | 0.18 |
| Surprise Percentage | 11.7647% | 9.0909% | -8.3333% | -87.5% | -75% | -37.5% | -91.3043% | -22.2222% | 12.9032% | 26.9231% | -17.8571% | 51.4286% |
Next Quarterly Earnings
| Aug 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: STIM
2026-08-04 12:12:27
Jorey Chernett, a major shareholder in Neuronetics, Inc. (STIM), has increased his beneficial ownership to 15.22% with 10,588,988 shares. He has acquired these shares using personal funds totaling approximately $20.68 million. Chernett and Neuronetics have reached an agreement granting him the opportunity to recommend a new board member, subject to standard approvals.
2026-08-01 17:10:41
Neuronetics (NASDAQ: STIM) has granted equity inducement awards in the form of restricted stock units (RSUs) to five new non-executive employees. These awards, made under the company's 2020 Inducement Incentive Plan and in accordance with Nasdaq Listing Rule 5635(c)(4), vest over three to four years, subject to continued employment. The grants were approved by Neuronetics' Compensation Committee to attract and retain key talent.
2026-08-01 05:10:45
Neuronetics, Inc. announced an inducement grant of restricted stock units (RSUs) to its new Chief Financial Officer, Matthew Bennett. This grant, totaling 167,490 RSUs, was made outside of the company's existing equity compensation plans but was approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually on the grant date, subject to Bennett's continued employment.
2026-07-31 05:00:00
Neuronetics, Inc. announced the granting of inducement awards to five new non-executive employees in accordance with NASDAQ Listing Rule 5635(c)(4). These awards, approved by Neuronetics’ Compensation Committee, were provided as a material inducement for their employment with the company. The restricted stock units (RSUs) have varying vesting schedules, subject to continued employment, and are part of the company's 2020 Inducement Incentive Plan.
2026-07-29 16:39:36
Neuronetics Inc (STIM) exhibits an institutional shareholding score of 5.00, placing it 107th within the Healthcare Equipment & Supplies industry. The company's institutional shareholding proportion recently increased by 11.24% quarter-over-quarter to 68.80%. The largest institutional shareholder is Bill Nygren | OAKMX, holding 5.49K shares.
2026-07-29 16:39:36
Neuronetics, Inc. (NASDAQ: STIM) announced the grand opening of Greenbrook Mental Wellness Centers’ National Center of Excellence in Rockville, Maryland, a significant investment in interventional psychiatry. The new 7,000-square-foot facility aims to expand access to advanced treatments for depression and other psychiatric conditions. Despite this development, STIM shares saw a slight decline of 1.1%, closing at $1.79.
